Answer
Yes, hepatotoxicity has been reported in a limited number of patients receiving Vocabria (cabotegravir), with or without known pre-existing liver disease.
Sources for this answer
- Vocabria 600 mg prolonged-release suspension for injectionViiV Healthcare UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 10Document updated
Sources checked